Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma

For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Qiankun, Ren, Haiyang, Li, Xiaodong, Qian, Bo, Fan, Shengjie, Hu, Fengli, Xu, Lishan, Zhai, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746348/
https://www.ncbi.nlm.nih.gov/pubmed/33203790
http://dx.doi.org/10.18632/aging.104028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746348/
https://www.ncbi.nlm.nih.gov/pubmed/33203790
http://dx.doi.org/10.18632/aging.104028

Ejemplares similares